AstraZeneia's heart failure drug Forxiga has been approved by the European Union

, of AstraZeneca, has been approved by the European Union to treat symptomatic heart failure with reduced blood test scores (HFrEF).
SGLT2 inhibitors have been approved for use in the treatment of adult patients with or without diabetes, expanding their potential coverage in the heart failure market.The European Commission's approval is based on the results of the DAPA-HF III clinical trial, which showed that Forxiga reduced the risk of
compound results by 26% compared to
placebo.
addition, both components of the main composite endpoint are helpful for the overall effect.
complex endpoint refers to the time of the first worsening heart failure event or cardiovascular death.
Forxiga has been approved in the United States under the commercial name Farxiga for the treatment of HFrEF patients, and is currently under review in Japan and several other
countries
world.

Forxiga's approval, we can redefine the standard of care for millions of heart failure patients in the European Union," said Mene Pangalos, executive vice president of biopharmaceutical research and development at AstraZenecon
.
added,
We
take another step toward achieving our goal of preventing or treating heart failure by providing treatments that significantly reduce cardiovascular death and hospitalization. In, heart failure affects about 15 million people, at least half of whom have lower blood test scores. This occurs when the left myocardial muscle does not contract sufficiently and therefore discharges less oxygen-rich blood into the body.
(cyy123.com
)

: